Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A major trial just showed that transcatheter tricuspid valve repair isn't just about feeling better — it saves lives. The TRIC-I-HF study found that adding the minimally invasive repair to standard medical therapy cut the combined risk of death and heart failure hospitalization by 60% over 3 years, compared to medication alone. It's the first time a tricuspid repair trial has scored wins on these hard clinical endpoints.
For years, transcatheter tricuspid valve repair has been celebrated for improving quality of life — but critics wanted proof it could move the needle on harder outcomes. The TRIC-I-HF trial, presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine, delivers exactly that. In 360 patients with symptomatic severe tricuspid regurgitation and heart failure, adding transcatheter repair to optimal medical therapy slashed the combined risk of all-cause death and HF hospitalization by 60% relative to medication alone — with benefits emerging early and holding strong through 3 years.
The trial enrolled a notably sick, elderly population (mean age 80.3 years, 75% with NYHA class III/IV HF), and results were driven by high-volume centers with deep procedural experience — a factor researchers say likely contributed to the stronger outcomes versus prior trials.
By the Numbers:
Why it matters: This is the first tricuspid repair trial to demonstrate meaningful reductions in mortality and HF hospitalization — not just symptom relief. Experts say the data will reshape guidelines and expand treatment access for a patient population with historically limited options.
